F-star Therapeutics, Inc.

NasdaqCM:FSTX Stock Report

Market Cap: US$156.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

F-star Therapeutics Management

Management criteria checks 2/4

Key information

Eliot Forster

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage23.7%
CEO tenure2.3yrs
CEO ownership1.3%
Management average tenure2.3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

F-star Therapeutics: Running Into A National Security Roadblock

Sep 22

F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale

Sep 15

F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon

Jul 29

F-star enters license deal with Takeda for a cancer immune therapy antibody

Jul 20

Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues

May 18
Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues

US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results

Mar 17
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results

These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts

Mar 16
These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts

F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers

Jan 27

F-star Therapeutics under pressure on pricing $65M stock offering

May 07

Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like

Mar 17
Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like

Merck KGaA discloses 5.4% stake in F-star Therapeutics

Feb 02

Dosing underway in early-stage study of F-star's FS120 in cancer

Dec 03

CEO Compensation Analysis

How has Eliot Forster's remuneration changed compared to F-star Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$3mUS$665k

-US$31m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$5mUS$645k

-US$26m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$2mUS$436k

-US$23m

Compensation vs Market: Eliot's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Eliot's compensation has been consistent with company performance over the past year.


CEO

Eliot Forster (56 yo)

2.3yrs

Tenure

US$2,801,895

Compensation

Dr. Eliot Richard Forster, Ph D, MBA, serves as CEO and President at F-star Therapeutics, Inc. since, November 20, 2020 and serves as its Director. Dr. Forster served as Interim Supervisory Director at Imm...


Leadership Team

NamePositionTenureCompensationOwnership
Eliot Forster
President2.3yrsUS$2.80m1.27%
$ 2.0m
Darlene Deptula-Hicks
CFO, Treasurer & Secretary3.8yrsUS$1.14m0%
$ 0
Neil Brewis
Chief Scientific Officerno dataUS$838.42k0.44%
$ 686.8k
Louis Kayitalire
Chief Medical Officer2.3yrsUS$933.66k0%
$ 0
Lindsey Trickett
Vice President of Investor Relations & Communicationsno datano datano data
James Sandy
Chief Development Officerless than a yearno datano data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Management: FSTX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eliot Forster
Presidentno dataUS$2.80m1.27%
$ 2.0m
Todd Brady
Independent Director2.3yrsUS$155.10k0.068%
$ 106.8k
Geoffrey Race
Independent Director3.3yrsUS$167.94k0%
$ 0
Edward Benz
Independent Director3.3yrsUS$184.68k0%
$ 0
Nessan Bermingham
Independent Chairman3.8yrsUS$1.02m0%
$ 0
David Arkowitz
Independent Director2.3yrsUS$170.10k0.043%
$ 67.5k
Jedd Wolchok
Scientific Advisorno datano datano data
Pamela M. Klein
Independent Director2.3yrsUS$151.60k0%
$ 0
Charles Drake
Scientific Advisorno datano datano data
Ignacio Melero
Scientific Advisorno datano datano data
Rienk Offrin
Scientific Advisorno datano datano data
Dario Vignali
Scientific Advisorno datano datano data

2.8yrs

Average Tenure

61yo

Average Age

Experienced Board: FSTX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.